Comparison of CpG island methylator phenotype (CIMP) frequency in colon cancer using different probe- And gene-specific scoring alternatives on recommended multi-gene panels

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Berg, Marianne ^a,b   Hagland, Hanne R ^a   Søreide, Kjetil ^a,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF STAVANGER   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; NEUROGENIN 1; PROTEIN MLH1; SOMATOMEDIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3;

ARTICLE; CANCER CELL; CANCER STAGING; COLON CANCER; COLORECTAL CANCER; CPG ISLAND; DNA ISOLATION; HUMAN; HUMAN TISSUE; METHYLATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PHENOTYPE; PREVALENCE;

CELL LINE, TUMOR; COLONIC NEOPLASMS; CPG ISLANDS; DNA METHYLATION; HUMANS; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84907020986     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086657     Document Type: Article

References (25)

1. Goel A, Boland CR (2012) Epigenetics of colorectal cancer. Gastroenterology 143: 1442-1460 e1441.
2. Berg M, Soreide K Genetic and epigenetic traits as biomarkers in colorectal cancer. IntJMolSci 12: 9426-9439.
3. Hagland HR, Berg M, Jolma IW, Carlsen A, Soreide K (2013) Molecular Pathways and Cellular Metabolism in Colorectal Cancer. Dig Surg 30: 12-25.
4. Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, et al. (2008) Hypermethylated MAL gene - a silent marker of early colon tumorigenesis. JTranslMed 6: 13.
5. Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, et al. (2009) Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. BrJSurg 96: 1196-1204.
6. Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, et al. (2008) A simplified, noninvasive stool DNA test for colorectal cancer detection. AmJGastroenterol 103: 2862-2870.
7. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC, III, et al. (2007) Improved fecal DNA test for colorectal cancer screening. ClinGastroenterolHepatol 5: 111-117. (Pubitemid 46096834)
8. Ned RM, Melillo S, Marrone M Fecal DNA testing for Colorectal Cancer Screening: the ColoSure test. PLoSCurr 3:RRN1220.: RRN1220.
9. Heichman KA, Warren JD (2012) DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 50: 1707-1721.
10. deVos T, Tetzner R, Model F, Weiss G, Schuster M, et al. (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. ClinChem 55: 1337-1346.
11. Simons CC, Hughes LA, Smits KM, Khalid-de Bakker CA, de Bruine AP, et al. (2013) A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann Oncol.
12. Lange CP, Laird PW (2013) Clinical applications of DNA methylation biomarkers in colorectal cancer. Epigenomics 5: 105-108.
13. Issa JP (2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-993.
14. Issa JP (2000) The epigenetics of colorectal cancer. AnnNYAcadSci 910: 140-153.
15. Karpinski P, Walter M, Szmida E, Ramsey D, Misiak B, et al. (2013) Intermediate- and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and -zero) in colorectal cancer. Cancer Epidemiol Biomarkers Prev 22: 201-208.
16. Ashktorab H, Rahi H, Wansley D, Varma S, Shokrani B, et al. (2013) Toward a comprehensive and systematic methylome signature in colorectal cancers. Epigenetics 8: 807-815.
17. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, et al. (2012) Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 22: 271-282.
18. Kaneda A, Yagi K (2011) Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Cancer Sci 102: 18-24.
19. Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, et al. (2013) The CpG island methylator phenotype: what's in a name? Cancer Res.
20. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, et al. (2007) Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 9: 305-314. (Pubitemid 47305066)
21. Nordgard O, Oltedal S, Korner H, Aasprong OG, Tjensvoll K, et al. (2009) The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR. IntJColorectal Dis 24: 261-268.
22. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, et al. (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87: 1055-1065. (Pubitemid 47429190)
23. Stuppia L, Antonucci I, Palka G, Gatta V (2012) Use of the MLPA Assay in the Molecular Diagnosis of Gene Copy Number Alterations in Human Genetic Diseases. Int J Mol Sci 13: 3245-3276.
24. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793. (Pubitemid 43980599)
25. Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, et al. (2013) Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 26: 465-484.